About Sirius Genomics
Developer of diagnostics and pharmacogenetic tests for critical care medicine. The company develops DNA-based diagnostic (Dx) and pharmacogenetic (PGx) tests for critical care. The main product focus is concentrated on the development of Dx and PGx tests for sepsis, a systemic blood infection. [Keywords: personalized medicine]
Missing: Sirius Genomics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Sirius Genomics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Sirius Genomics Frequently Asked Questions (FAQ)
When was Sirius Genomics founded?
Sirius Genomics was founded in 2001.
Where is Sirius Genomics's headquarters?
Sirius Genomics's headquarters is located at 1125 Howe Street, Suite 603, Vancouver.
What is Sirius Genomics's latest funding round?
Sirius Genomics's latest funding round is Grant.
How much did Sirius Genomics raise?
Sirius Genomics raised a total of $5.1M.
Who are the investors of Sirius Genomics?
Investors of Sirius Genomics include National Research Council Canada.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.